Valuation: Medexus Pharmaceuticals Inc.

Market Cap 155M 108M 96.44M 89.88M 81.96M 10.45B 156M 1.09B 422M 5.33B 407M 399M 17.13B P/E 2027 *
21.4x
P/E 2028 * 5.94x
Enterprise Value 155M 108M 96.44M 89.88M 81.96M 10.45B 156M 1.09B 422M 5.33B 407M 399M 17.13B EV / Sales 2027 *
0.95x
EV / Sales 2028 * 0.79x
Free-Float
93.53%
Yield 2027 *
-
Yield 2028 * -

Last Transcript: Medexus Pharmaceuticals Inc.

1 day-4.07%
1 week-6.35%
Current month-5.60%
1 month-9.75%
3 months-7.45%
6 months+43.90%
Current year+62.20%
1 week 4.57
Extreme 4.57
5.13
1 month 4.57
Extreme 4.57
5.27
Current year 2.65
Extreme 2.65
5.5
1 year 2.51
Extreme 2.51
5.5
3 years 1.44
Extreme 1.44
5.56
5 years 0.88
Extreme 0.88
5.56
10 years 0.88
Extreme 0.88
9.75
Manager TitleAgeSince
Chief Executive Officer - 17/12/2018
Director of Finance/CFO - 01/06/2019
General Counsel - 08/11/2021
Director TitleAgeSince
Chairman 66 11/04/2023
Director/Board Member - 22/09/2017
Director/Board Member - 16/10/2018
Date Insider Type Main position Quantity % Market Cap. Importance
8/21/26 A TaxCompany -1,000 0.0032% -
8/21/26 A TaxCompany 1,000 0.0032% -
8/20/26 A TaxCompany -8,100 0.0258%
Change 5-day change 1-year change 3-year change Capi.($)
-4.07%-6.35%+84.38%+54.75% 109M
-0.61%-3.30%+38.46%+112.77% 1,025B
-1.02%-5.41%+37.61%+64.39% 623B
+1.11%-0.87%+7.55%+76.32% 459B
+0.34%-2.49%+60.10%+40.17% 355B
-0.95%-4.87%+22.46%+38.03% 336B
-1.46%-2.20%+11.84%+23.94% 270B
-1.35%-4.27%-4.55%+6.92% 247B
-1.04%-0.74%+35.02%+49.96% 220B
-1.87%-3.31%+30.22%+93.14% 183B
Average -0.77%-1.94%+32.31%+56.04% 371.83B
Weighted average by Cap. -0.32%-2.11%+29.72%+68.31%

Financials

2027 *2028 *
Net sales 163M 114M 102M 94.85M 86.49M 11.03B 165M 1.15B 445M 5.62B 430M 421M 18.08B 197M 138M 123M 114M 104M 13.28B 199M 1.38B 536M 6.77B 518M 507M 21.77B
Net income 7.47M 5.24M 4.66M 4.34M 3.96M 505M 7.54M 52.61M 20.37M 257M 19.68M 19.25M 827M 26.89M 18.86M 16.77M 15.63M 14.26M 1.82B 27.17M 189M 73.37M 927M 70.87M 69.34M 2.98B
Net Debt - -
Logo Medexus Pharmaceuticals Inc.
Medexus Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company with a North American commercial platform. The Company has a portfolio of rare disease treatment solutions. Its focus is on the therapeutic areas of hematology-oncology and allergy, dermatology, and rheumatology. It operates through two product portfolios: Medexus Pharma Canada and Medexus Pharma. Its lead products are IXINITY (US), GRAFAPEX (US), Trecondyv (Canada), Rupall (Canada), Rasuvo (US), Metoject (Canada), and Gleolan (US). IXINITY (US) is an intravenous recombinant factor IX therapeutic for use in patients with hemophilia B. Rupall (Canada) is a prescription allergy medication with a mode of action. Rasuvo (US) and Metoject (Canada) is a formulation of methotrexate designed to treat rheumatoid arthritis and other autoimmune diseases. Gleolan (US) is an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.
Employees
90
Date Price Change Volume
02/10/26 CA$4.720 -4.07% 106,433
01/10/26 CA$4.920 -1.60% 24,832
30/09/26 CA$5.000 0.00% 56,784
29/09/26 CA$5.000 -2.34% 38,303
28/09/26 CA$5.120 0.00% 15,975
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
4.720CAD
Average target price
7.250CAD
Spread / Average Target
+53.60%

Quarterly revenue - Rate of surprise